16 recruiting, 13 completed, 10 unknown, 4 active not recruiting. 20 Phase 2, 12 Phase 1, 7 Not applicable, 4 Phase 3, 2 Phase 4.
Follow Breast Cancer Stage IV: new trials by email Literature Review of Breast Cancer Stage IV trials Research Report on Breast Cancer Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer Meaning-Centered Psychotherapy for Latinos /MCP-L - Breast Cancer, Prostate Cancer | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 300 | 2026-05-01 | 2026-08-03 |
| HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd) - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-03-04 | 2026-08-20 |
| Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management Digital Health Tools, T-DXd, Pertuzumab - Breast Cancer Stage IV | Phase 2 | Recruiting | SOLTI Breast Cancer Research Group | 300 | 2026-02-18 | 2026-03-27 |
| HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC Positron emission tomografy with [68Ga]Ga-ABY-025 - Breast Cancer Stage IV, HER2-low Breast Cancer | Recruiting | Renske Altena | 70 | 2025-10-03 | 2025-11-20 | |
| Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy trastuzumab derxutecan - Breast Cancer Metastatic, Breast Cancer Stage IV | Phase 2 | Enrolling by invitation | UNICANCER | 80 | 2025-07-30 | 2026-08-03 |
| Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer Camrelizumab+Apatinib+Eribulin, Physician's choice chemotherapy - Breast Cancer Stage IV, Triple -Negative Breast Cancer | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 246 | 2025-02-21 | 2026-04-23 |
| A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer Abemaciclib, Radiation Therapy - Metastatic Breast Cancer, Stage IV Breast Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 28 | 2024-11-15 | 2026-05-28 |
| A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients. Lutetium-177-DOTAGA-IAC - Breast Cancer Stage IV | Phase 1 / Phase 2 | Unknown | Advanced Imaging Projects, LLC | 100 | 2024-09-30 | 2024-04-10 |
| Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer Inetetamab and Paclitaxel ± Pertuzumab - Breast Cancer Stage IV | Phase 4 | Not yet recruiting | Fudan University | 100 | 2024-08-30 | 2024-08-29 |
| Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Tart Cherry Juice - Breast Cancer, Breast Cancer Stage I | Phase 2 | Recruiting | University of California, Davis | 86 | 2024-08-15 | 2026-03-04 |
| HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan Sacituzumab Govitecan - Breast Cancer Stage IV | Phase 2 | Recruiting | SOLTI Breast Cancer Research Group | 50 | 2024-03-15 | 2024-07-19 |
| RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study Trastuzumab deruxtecan (DS-8201a) - Radiomic, Radiomics | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 500 | 2024-02-01 | 2025-06-22 | |
| A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer Pembrolizumab, Cryoablation, Histotripsy - Metastatic Breast Cancer, Breast Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2024-01-29 | 2026-09-14 |
| Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study Breast Cancer, Breast Neoplasms | Completed | Medical College of Wisconsin | 125 | 2023-12-08 | 2026-08-27 | |
| A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer MBQ-167 - Breast Cancer, Breast Neoplasm | Phase 1 | Recruiting | MBQ Pharma | 48 | 2023-11-09 | 2026-08-31 |
| Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib Alpelisib, Ribociclib - Breast Cancer Stage IV | Phase 2 | Terminated | UNICANCER | 4 | 2023-10-19 | 2026-10-14 |
| Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis Huaier Granule - Breast Cancer Stage IV | Phase 4 | Not yet recruiting | Fudan University | 384 | 2023-10-01 | 2023-09-26 |
| A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. FWD1802 - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 1 / Phase 2 | Recruiting | Forward Pharmaceuticals Co., Ltd. | 99 | 2023-09-12 | 2026-02-10 |
| Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases Datopotamab deruxtecan - Breast Cancer Stage IV | Phase 2 | Recruiting | Medical University of Vienna | 20 | 2023-07-01 | 2025-09-25 |
| Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients Communication model - Breast Cancer Stage IV, Breast Cancer Metastatic | Not applicable | Completed | Medicos e Investigadores en la Lucha contra el Cancer de Mama | 100 | 2023-05-17 | 2025-02-07 |
Showing 20 of 51. Sign in to see all of them.
Breast Neoplasms (51) · Ovarian Neoplasms (5) · Neoplasm Metastasis (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Stomach Neoplasms (2) · Thyroid Neoplasms (2) · Breast Carcinoma In Situ (1) · Breast Diseases (1) · Breast Neoplasms, Male (1) · Carcinoma, Squamous Cell (1) · Cardiotoxicity (1) · Colorectal Neoplasms (1) · Communication (1)
Neoplasms by Site (51) · Skin Diseases (51) · Skin and Connective Tissue Diseases (51) · Breast Diseases (50) · Neoplasms (50) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Genital Diseases (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Adnexal Diseases (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5)
Fulvestrant (4) · palbociclib (4) · Alpelisib (3) · abemaciclib (3) · ribociclib (3) · trastuzumab deruxtecan (3) · Blood Specimen Collection (2) · pertuzumab (2) · Albumin-Bound Paclitaxel (1) · Anastrozole (1) · Ascorbic Acid (1) · Canagliflozin (1) · Carboplatin (1) · Carmustine (1) · Cryosurgery (1)
Memorial Sloan Kettering Cancer Center (8) · UNICANCER (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Fudan University (2) · Medical University of Vienna (2) · SOLTI Breast Cancer Research Group (2) · Advanced Imaging Projects, LLC (1) · Baylor Breast Care Center (1) · Blokhin's Russian Cancer Research Center (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Charite University, Berlin, Germany (1) · Dana-Farber Cancer Institute (1) · Eske Corporation S.A.C (1) · Exactis Innovation (1) · Forward Pharmaceuticals Co., Ltd. (1)
United States (20) · China (5) · France (4) · Italy (3) · Austria (2) · Germany (2) · Mexico (2) · Spain (2) · Sweden (2) · Belgium (1) · Brazil (1) · Canada (1) · Egypt (1) · Greece (1) · India (1)
Jian Zhang (2) · Alina Markova, MD (1) · Alison Conlin, MD (1) · Anthony Yu, MD (1) · Arnold Glazier, M.D. (1) · Barbro K Linderholm, MD, PhD (1) · C. Kent Osborne, MD (1) · Chandler S Cortina (1) · Claire Bonneau, MD (1) · Devika Jutagir, PhD (1) · Enrique Freitas, MD (1) · Eva Ciruelos, MD (1) · Eve Rodler, MD (1) · Ezra Rosen, MD, PhD (1)
PMID 22853992, PMID 25945808, PMID 32817060, PMID 35843174, PMID 35941372, PMID 36215125, PMID 37475004, PMID 37986940, PMID 38045318, PMID 38446316, PMID 38553649, PMID 39417128, PMID 39702320, PMID 40313865, PMID 40588378, PMID 42038396, PMID 42473551
2025 (1)